Lionco Pharmaceutical Group Co.,Ltd. - Laporan Laba Rugi (TTM)

Lionco Pharmaceutical Group Co.,Ltd.
CN ˙ SHSE
CN¥ 6.00 ↑0.21 (3.63%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Lionco Pharmaceutical Group Co.,Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1,194 1,001 1,015 1,005 885 740 592 463 338 289 237 202 189 197 200 225 277 380 353 410
Change (%) -16.14 1.43 -1.00 -11.96 -16.35 -19.99 -21.89 -27.04 -14.31 -18.22 -14.65 -6.53 4.30 1.81 12.48 22.99 37.01 -7.04 16.11
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 176 165 166 171 167 156 143 114 100 95 94 118 115 110 115 130 162 207 210 270
Change (%) -6.20 0.39 3.22 -2.57 -6.81 -8.16 -20.56 -11.90 -5.56 -0.47 25.39 -2.42 -4.55 4.97 12.72 24.74 27.34 1.48 28.73
% of Revenue 14.78 16.53 16.36 17.06 18.88 21.03 24.14 24.55 29.65 32.68 39.77 58.43 61.00 55.82 57.55 57.68 58.51 54.38 59.37 65.82
Gross Operating Profit 1,017 836 849 834 718 585 449 349 237 195 142 84 74 87 85 95 115 173 143 140
Change (%) -17.86 1.63 -1.82 -13.89 -18.56 -23.14 -22.32 -31.97 -18.00 -26.83 -41.09 -12.31 18.14 -2.19 12.14 20.59 50.63 -17.20 -2.33
% of Revenue 85.22 83.47 83.64 82.94 81.12 78.97 75.86 75.45 70.35 67.32 60.23 41.57 39.00 44.18 42.45 42.32 41.49 45.62 40.63 34.18
SG&A 848 699 708 694 596 514 403 295 305 334 325 328 250 223 215 215 219 251 214 207
Change (%) -17.59 1.25 -1.93 -14.19 -13.74 -21.56 -26.82 3.41 9.47 -2.62 0.82 -23.61 -11.02 -3.43 -0.05 1.69 14.81 -14.58 -3.30
% of Revenue 71.08 69.84 69.72 69.06 67.31 69.40 68.04 63.74 90.35 115.41 137.42 162.34 132.67 113.19 107.37 95.42 78.90 66.11 60.75 50.59
R&D 16 20 18 21 26 23 22 21 22 32 33 34 35 29 30 26 23 27 26 21
Change (%) 27.10 -9.24 15.05 22.52 -12.59 -3.27 -4.11 4.03 43.91 5.16 3.06 2.10 -16.77 4.47 -13.03 -13.52 16.51 -3.60 -18.09
% of Revenue 1.34 2.03 1.82 2.12 2.94 3.08 3.72 4.57 6.51 10.93 14.06 16.97 18.54 14.80 15.18 11.74 8.26 7.02 7.28 5.14
OpEx 1,008 898 939 933 864 702 577 436 458 466 457 480 371 367 361 381 426 489 460 503
Change (%) -10.90 4.53 -0.60 -7.42 -18.77 -17.86 -24.33 4.88 1.91 -2.04 5.08 -22.68 -1.17 -1.63 5.69 11.81 14.70 -5.87 9.37
% of Revenue 84.48 89.74 92.49 92.86 97.65 94.81 97.33 94.29 135.55 161.20 193.10 237.75 196.68 186.36 180.06 169.19 153.82 128.77 130.39 122.82
Operating Income 185 103 76 72 21 38 16 26 -120 -177 -220 -278 -182 -170 -160 -156 -149 -109 -107 -94
Change (%) -44.60 -25.69 -5.92 -70.97 84.42 -58.81 66.83 -554.52 47.53 24.40 26.28 -34.40 -6.83 -5.62 -2.79 -4.34 -26.75 -1.82 -12.79
% of Revenue 15.52 10.26 7.51 7.14 2.35 5.19 2.67 5.71 -35.55 -61.20 -93.10 -137.75 -96.68 -86.36 -80.06 -69.19 -53.82 -28.77 -30.39 -22.82
Interest Expense -14 -11 -14 -15 -14 -16 -14 -12 -11 -6 -4 -3 -3 -4 -3 -3 -7 -27 -32 -36
Change (%) -18.28 21.03 9.32 -4.22 8.79 -10.65 -10.92 -13.94 -45.11 -25.78 -31.22 -7.18 34.26 -26.80 18.97 125.02 276.58 17.91 11.87
% of Revenue -1.15 -1.12 -1.34 -1.48 -1.61 -2.10 -2.34 -2.67 -3.15 -2.02 -1.83 -1.47 -1.46 -1.88 -1.36 -1.43 -2.62 -7.21 -9.14 -8.81
Net Income 203 160 129 153 87 66 51 33 -82 -196 -239 -301 -223 -151 -145 -122 -102 -131 -133 -126
Change (%) -21.24 -19.31 18.11 -43.24 -23.90 -22.07 -35.73 -349.81 137.54 22.24 25.92 -26.04 -32.06 -4.59 -15.48 -16.67 28.45 1.97 -5.43
% of Revenue 17.03 15.99 12.72 15.18 9.79 8.90 8.67 7.13 -24.43 -67.71 -101.20 -149.31 -118.15 -76.97 -72.13 -54.21 -36.73 -34.43 -37.77 -30.76

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista